Latest Oncology News

Anlotinib/Sintilimab Combo Confers Long-Term OS Benefit in Advanced Cervical Cancer

Anlotinib/Sintilimab Combo Confers Long-Term OS Benefit in Advanced Cervical Cancer

June 27th 2022

Jason Harris

The combination of anlotinib and sintilimab was found to provide a long-term survival benefit to patients with previously treated advanced cervical cancer.

CHMP Supports Approval for Trastuzumab Deruxtecan in Metastatic HER2-Positive Breast Cancer

CHMP Supports Approval for Trastuzumab Deruxtecan in Metastatic HER2-Positive Breast Cancer

June 27th 2022

Chris Ryan

The European Medicines Agency’s Committee for Medicinal Products for Human Use recommended the approval of trastuzumab deruxtecan monotherapy for patients with metastatic HER2-positive breast cancer who have received at least 1 prior anti–HER2-based regimen.

Japanese Regulatory Approval Sought for Trastuzumab Deruxtecan in HER2-Low Metastatic Breast Cancer

Japanese Regulatory Approval Sought for Trastuzumab Deruxtecan in HER2-Low Metastatic Breast Cancer

June 27th 2022

Jason Harris

A supplemental New Drug Application has been submitted to Japan’s Ministry of Health, Labour, and Welfare seeking approval for use of trastuzumab deruxtecan for the treatment of adult patients with HER2-low unresectable or recurrent metastatic breast cancer following chemotherapy

Sylvester Researchers Uncover New Cellular Oxygen-Sensing Pathway

Sylvester Researchers Uncover New Cellular Oxygen-Sensing Pathway

June 27th 2022

Sylvester Comprehensive Cancer Center

A team of researchers with Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine has identified a new cellular oxygen-sensing pathway – a discovery that could potentially lead to new approaches for treating cancer and other diseases.

TX05 Provides Comparable DFS Benefit to Trastuzumab in Early-Stage HER2+ Breast Cancer

TX05 Provides Comparable DFS Benefit to Trastuzumab in Early-Stage HER2+ Breast Cancer

June 27th 2022

Chris Ryan

Adjuvant treatment with TX05 resulted in a similar disease-free survival benefit to that of trastuzumab in patients with early-stage HER2-positive breast cancer.

Latest Oncology Videos

All Oncology News

FDA Approval Sought for Elacestrant in ER+/HER2- Breast Cancer

June 23rd 2022

Kristi Rosa

A new drug application has been submitted to the FDA seeking the approval of elacestrant in the treatment of patients with estrogen receptor–positive, HER2-negative, advanced or metastatic breast cancer.

Crenolanib Plus Chemotherapy Provides Long-Term Survival Benefit in FLT3-Mutant AML

June 23rd 2022

Ashling Wahner

Eunice Wang, MD, discusses the long-term results of a phase 2 trial investigating crenolanib plus chemotherapy in adult patients with newly diagnosed FLT3-mutant acute myeloid leukemia.

HPN328 Elicits Antitumor Activity in Small Cell Lung Cancer and Other NETs

June 23rd 2022

Caroline Seymour

HPN328, a novel half-life extended DLL3-targeting T-cell engager, demonstrated clinical activity and tolerability in patients with pretreated small cell lung cancer and other neuroendocrine tumors, according to findings from a phase 1/2 study (NCT04471727).

Sylvester Announces Transformational Cancer Research Building

June 23rd 2022

Sylvester Comprehensive Cancer Center

Sylvester Comprehensive Cancer Center is making another bold move to accelerate cancer research, celebrating the groundbreaking for a 244,000-square-foot, state-of-the-art Sylvester Comprehensive Cancer Center - Transformational Cancer Research Building.

NCCN Adds Trastuzumab Deruxtecan, Sacituzumab Govitecan to Guidelines for Advanced Breast Cancer

June 23rd 2022

Jason Harris

“Compelling” data support the use of trastuzumab deruxtecan in patients with HER2-low metastatic breast cancer and the use of sacituzumab govitecan for patients with triple-negative breast cancer or hormone receptor–positive, HER2-negative disease.

Referring Patients with Basal Cell Carcinoma to Medical Oncology

June 23rd 2022

Jennifer L. Atlas, MD

Dr. Shahab Babakoohi explains when to refer a patient with basal cell carcinoma from a dermatology practice to a medical oncologist.

Clinical Pearls for the Management of Myelofibrosis

June 23rd 2022

Stephen Oh, MD, PhD

Closing out their discussion on myelofibrosis, experts provide practical advice for identifying and managing patients in real-world practice.

FDA Approves Dabrafenib Plus Trametinib for BRAF V600E–Mutated Unresectable or Metastatic Solid Tumors

June 22nd 2022

Kristi Rosa

The FDA has granted an accelerated approval to dabrafenib plus trametinib for the treatment of adult and pediatric patients aged 6 years and older with unresectable or metastatic solid tumors harboring a BRAF V600E mutation who have progressed following previous treatment and who have no satisfactory alternative treatment options.

Final Analysis from AMPECT, an Open-Label Phase 2 Registration Trial of nab-SIROLIMUS for Patients With Advanced Malignant Perivascular Epithelioid Cell Tumors (PEComa)

June 22nd 2022

Vinod Ravi, MD, MS, MBA

Dr Vinod Ravi talks about nab-SIROLIMUS and reviews the data from the AMPECT trial.

FDA Grants Orphan Drug Designation to VBI-1901 for Glioblastoma

June 22nd 2022

Chris Ryan

The FDA has granted an orphan drug designation to VBI-1901, a novel cancer immunotherapeutic vaccine candidate, as a potential therapeutic option for patients with glioblastoma.

UK’s MHRA Accepts Marketing Authorization Application for Aumolertinib in EGFR+ NSCLC

June 22nd 2022

Caroline Seymour

The United Kingdom’s Medicines and Healthcare Products Regulatory Agency accepted for review the marketing authorization application for aumolertinib for the first-line treatment of adult patients with locally advanced or metastatic non–small cell lung cancer with activating EGFR mutations and locally advanced/metastatic EGFR T790M mutation–positive non–small cell lung cancer.

FDA Grants Orphan Drug Designation to MB-106 for Waldenström Macroglobulinemia

June 22nd 2022

Kristi Rosa

The FDA has granted an orphan drug designation to the CD20-targeted autologous CAR T-cell therapy, MB-106, for use as a potential therapeutic option in patients with Waldenström macroglobulinemia.

New USPSTF Guidelines Increase Lung Cancer Screening Among African Americans

June 22nd 2022

Jason Harris

The US Preventive Services Task Force updated its lung cancer screening guidelines in 2021 to include more members of vulnerable populations, including African Americans, women, and the LGBTQ community.

EMA Accepts Type II Application for Trastuzumab Deruxtecan for Previously Treated HER2-Low Advanced Breast Cancer

June 22nd 2022

Jason Harris

The European Medicines Agency has validated a Type II Variation application for trastuzumab deruxtecan as monotherapy for adults with unresectable or metastatic HER2-low breast cancer.

Dr. DeAngelo on Rates of CRS with Obe-cel in ALL

June 22nd 2022

Daniel J. DeAngelo, MD, PhD

Daniel J. DeAngelo, MD, PhD, discusses rates of cytokine release syndrome with obecabtagene autoleucel in acute lymphoblastic leukemia.

See All News